Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pseudo-PDT in Central Serous Chorioretinopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02799992
Recruitment Status : Unknown
Verified June 2016 by Andrea Russo, Università degli Studi di Brescia.
Recruitment status was:  Not yet recruiting
First Posted : June 15, 2016
Last Update Posted : June 15, 2016
Sponsor:
Information provided by (Responsible Party):
Andrea Russo, Università degli Studi di Brescia

Brief Summary:

Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC.

Twenty-two eyes of 22 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689-LT delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between groups.


Condition or disease Intervention/treatment Phase
Chronic Central Serous Chorioretinopathy Procedure: 689 nm Laser Treatment of the Macula Procedure: Half Dose Photodynamic Therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : June 2016
Estimated Primary Completion Date : September 2016
Estimated Study Completion Date : September 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Half Dose Photodynamic Therapy
Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
Procedure: Half Dose Photodynamic Therapy
Experimental: 689 nm Laser Treatment
A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
Procedure: 689 nm Laser Treatment of the Macula



Primary Outcome Measures :
  1. Best-corrected Visual Acuity (LogMAR) [ Time Frame: 6 months ]
    Measured with ETDRS chart

  2. Central Retinal Thickness (micron) [ Time Frame: 6 months ]
    Measured with OCT

  3. Subfoveal Choroidal Thickness (micron) [ Time Frame: 6 months ]
    Measured with OCT


Secondary Outcome Measures :
  1. Ellipsoid Zone Recovery (integrity of IS/OS line) [ Time Frame: 6 months ]
    As visible with OCT scans



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age ≥18 years;
  • patients with best-corrected visual acuity (BCVA) of 20/200 or better;
  • presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment involving the fovea on optical coherence tomography (OCT);
  • presence of active angiographic leakage in fluorescein angiography caused by CSC and no other diseases, and abnormal dilated choroidal vasculature and other features in indocyanine green angiography (ICGA) consistent with the diagnosis of CSC.

Exclusion Criteria:

  • any previous treatment for CSC;
  • evidence of choroidal neovascularization or other maculopathy on fundus examination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02799992


Contacts
Layout table for location contacts
Contact: Andrea Russo, MD, PhD +390303995308 dott.andrea.russo@gmail.com

Sponsors and Collaborators
Università degli Studi di Brescia
Layout table for additonal information
Responsible Party: Andrea Russo, MD, PhD Candidate, Università degli Studi di Brescia
ClinicalTrials.gov Identifier: NCT02799992    
Other Study ID Numbers: CSC0001
First Posted: June 15, 2016    Key Record Dates
Last Update Posted: June 15, 2016
Last Verified: June 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases